EU-funded researchers have developed and tested a way to make human heart valve implants more tolerable and longer lasting, enabling recipients of all ages to avoid follow-up surgery and live largely normal lives, cutting hospital stays and healthcare costs.
Evaluation of the Innovative Medicines Initiative now published
The reports on the evaluation of the seven public-private partnerships, the so-called Joint Undertakings (JUs) under Horizon 2020, and their six predecessors under the previous seventh framework programme, have been published. This includes a Staff Working Document presenting the Commission services' view on the performance of the seven JUs under Horizon 2020. The experts concluded that the Innovative Medicines Initiative “remains both relevant and justified” under Horizon 2020 and that “positive contributions on the drug development process are expected, but results are yet to be realised as the first projects under IMI2 JU only started in 2014”.
- Staff Working Document
- Report on IMI JU Final Evaluation
- Report on IMI2 JU Interim Evaluation
- News Alert
EU–funded project aims at developing an effective Tuberculosis vaccine
Supported by Horizon 2020 with EUR 18.2m, TBVAC2020 research project aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. Over 50% of the global pipeline in TB vaccine candidates currently evaluated in clinical trials originate from EU–funded projects. The European Commission has played a key leadership role in accelerating TB vaccine research and development and ensured a well-coordinated and efficient TB vaccine research consortium.
Registration open! Health, demographic change and wellbeing Info Day
8 December 2017, Brussels
With the principle of better health for all at its core, Horizon 2020's Societal Challenge 1 (Health, demographic change and wellbeing) will be presented during the Health Information Day on 8 December 2017 in Brussels. Societal Challenge 1 (expected budget approx.. EUR 2 billion) focuses on personalised health and care, infectious diseases and improving global health, innovative and sustainable health systems, decoding the role of the environment (including climate change) for health and wellbeing, digital transformation and cybersecurity in health and care.
Related to the Health Open Info Day, the Directorate-General for Research & Innovation supports two events organised on 7 December 2017 (Brussels): Innovation Procurement in health care and the Partnering Event coordinated by the EU–funded project Health-NCP-Net 2.0.
Directorate-General Research & Innovation at the European Health Forum Gastein
DG Research & Innovation invites you to take part in the two interactive sessions organised at the European Health Forum Gastein:
- 4 October, 9:00-11:00, Personalising healthcare: How rare diseases pave the way
- 5 October, 16:00-18:30, Environment & health: Building the evidence base for policy
EU-funded project ALIVER produces new dialysis technology
EU-funded project ALIVER has developed and optimised a novel liver dialysis device called DIALIVE. By 2020 a new dialysis technology could be available and extend the lives of people with cirrhosis long enough for their liver to start recovering or to find a donor for a liver transplant.
EC and EIB grant EUR 20m loan to speed up solutions for the prevention and treatment of antibiotic–resistant infections
This key loan is designed to finance Da Volterra, a French biopharmaceutical company, toward the development in the area of prevention and treatment of antibiotic-resistant serious infectious and hospital-acquired diseases. This financial support is being provided under Horizon 2020, the current EU framework programme for research and innovation., and more particularly the InnovFin Infectious Diseases Finance Facility, which offers bespoke products for financing high-risk projects in the field of infectious diseases.
Personalised medicine days in Toulouse and LondonEU–funded project U-PGx aims to address major challenges and obstacles for the implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. As part of the dissemination and outreaching activities the project will organise the personalised medicine days:
- U-PGx Personalised Medicine Public Day, 17 November 2017, Toulouse, France, under the theme "Pharmacogenomics in Oncology: Deciphering the Ethical, Legal and Societal Issues"
- U-PGx Personalised Medicine Public Day, 6 December 2017, London, UK, under the theme "Is personalised medicine available for all citizens?"
- U-PGx project
16-19 October 2017, Bari, Italy - ISM – MYCOKEY Workshop – Training Course 2017 Strategies for minimization of mycotoxins and toxigenic fungi in food chains
24-27 October 2017, Berlin, Germany - DKOU 2017 - German Congress of Orthopedic and Trauma Surgery